Information on this page is provided as a guide and may change. Please verify details directly with the treatment center or other appropriate source before making care decisions.
UVA Comprehensive Cancer Center
Kidney Cancer Program
Address
1240 Lee StCharlottesville, VA, 22908
Key Contacts
Department Chair - Urology:
Dr. Kirsten Greene – Professor and Chair of Urology
Dr. Kirsten Greene – Professor and Chair of Urology
Urologic Surgery:
Dr. Allison May – Assistant Professor
Dr. Allison May – Assistant Professor
Urologic Surgery:
Dr. Stephen Culp – Professor
Dr. Stephen Culp – Professor
Medical Oncology:
Dr. Robert Dreicer – Professor and Deputy Director of UVA Cancer Center
Dr. Robert Dreicer – Professor and Deputy Director of UVA Cancer Center
Medical Oncology:
Dr. Paul Viscuse – Assistant Professor
Dr. Paul Viscuse – Assistant Professor
Radiation Oncology Lead:
Dr. Christopher Luminais – Assistant Professor
Dr. Christopher Luminais – Assistant Professor
Renal Tumor Ablation Lead:
Dr. Drew Lambert – Professor
Dr. Drew Lambert – Professor
Volume
Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.
Kidney Cancer Surgery Volume
MediumClear Cell Kidney Cancer Diagnosis Volume
HighNon–Clear Cell Kidney Cancer Diagnosis Volume
Very HighClinical Trial Participation Volume
HighRadiation & Ablation Procedure Volume
Very HighAbout these ratings
Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.
Types of Services Offered
Clinical Trials 
End of Life Services 
Genetic Counseling 
Infusion Center 
Integrative Oncology 
Molecular Testing 
Oncology Urgent Care Clinic 
Palliative & Supportive Care 
Patient Case Discussions / Tumor Boards 
Precision Medicine 
Survivorship Clinics 
Interventional Radiology 
Medical Oncology 
Pain Management 
Palliative Care 
Pathology 
Radiation Oncology 
Radiology 
Urologic Surgery Kidney Cancer Types & Expertise
Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)
Special Programs, Recognitions & Outcomes
American College of Surgeons Accredited Cancer Program Government-Funded Research Member of Kidney Cancer Consortium NCI Designated Cancer Center
Consortium Member
VHL Alliance, ORIEN, CHTN
Research Programs
Clinical 
Multi-Institutional Collaboration 
Population-Based 
Research Lab 
Translational Multi-Institutional Collaborations
University of Colorado Cancer Center / Anschutz Medical Campus
Moffitt Cancer Center
Huntsman Cancer Institute, University of Utah
Markey Cancer Center, University of Kentucky
Holden Comprehensive Cancer Center, University of Iowa
ORIEN
University of Michigan
Patient Resources & Support Services
Fertility Preservation Counseling 
Financial Navigators 
Interpreter Services 
Lodging / Long-Term Housing 
Lymphedema Therapy 
Nurse Navigators 
Nutrition Services / Dietician 
Occupational Therapy 
Parking Assistance (valet or concierge) 
Pastoral / Spiritual Care 
Patient Navigators 
Peer Support Options 
Physical Therapy 
Psychiatrists / Psychologists 
Social Workers / Counselors 
Transportation Service 
Wellness Center Insurance Carriers
Accepted
- Aetna
- Anthem Blue Cross Blue Shield
- Anthem HealthKeepers
- Cigna Healthcare of Virginia
- Custom Ink
- Everence
- First Health
- Gateway Health Alliance
- HealthSmart
- Medcost
- MultiPlan
- Optima Health / Sentara Health Plans
- Piedmont Community Health Plan
- UnitedHealthcare
- Virginia Medicaid
- Medicare
- TRICARE
- Virginia Premier
Insurance information is provided as a guide and may change. Participation can vary by plan, location, and individual coverage. Please contact the treatment center and your insurance provider directly to confirm that your specific insurance plan is currently accepted and to understand any applicable coverage requirements or costs.
Open Clinical Trials
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients with non-metastatic clear cell renal cell cancer may include surgery to completely remove the tumor. This typically involves removing the kidney or part of the kidney (nephrectomy). Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant botensilimab and balstilimab may be safe, tolerable, and/or effective in treating patients with high-risk non-metastatic clear cell renal cell cancer before undergoing a nephrectomy.
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.<br />
<br />
In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.